Aarey Drugs & Pharmaceuticals
Healthcare
AAREYDRUGS NSE
₹109.29 +3.53 (+3.34%)
- P/E
- Not meaningful: last twelve months’ earnings are mostly a one-off item
Close 4 Nov 2026 ₹109.29 +10.04 +10.1% 1Y
Start ₹99.25
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Standalone · TTM
- ROCE
- 5.58%
- Debt to Equity
- 0.33
- EPS (TTM)
- ₹1.47
- Book Value
- ₹53.28
- Market Cap
- —
- P/E (TTM)
- Not meaningful: last twelve months’ earnings are mostly a one-off item
- P/B
- 2.05
- ROE
- 2.75%
- Dividend Yield
- 0.00%
- EBITDA
- ₹13.30 Cr
- 52W High
- ₹114.80
- 52W Low
- ₹50.31
- Day Range
- ₹103.01 – ₹109.80
- Volume
- 86,084
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Aarey Drugs & Pharmaceuticals (this company) | ₹109.29 | — | ₹301 Cr | 2.05 | 0.00% | 2.75% | 5.58% | ₹415 Cr | ₹4 Cr |
| Median 8 companies | ₹1,587.70 | 38.81 | ₹1,25,337 Cr | 4.57 | 0.44% | 16.25% | 16.65% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
42 Weak
Data confidence 100/100
surveillance:ASM1
Category scores
- Quality
- 58
- Good
- Returns, margins, earnings quality 22% weight
- Valuation
- 28
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 27
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 38
- Weak
- Solvency, leverage, coverage 9% weight
- Momentum
- 88
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 39
- Weak
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Promoter holding has increased by 5.08% over last quarter.
Weaknesses
6- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 6.27% over past five years.
- Company has a low return on equity of 3.13% over last 3 years.
- Earnings include an other income of Rs.6.26 Cr.
- Promoter holding has decreased over last 3 years: -7.25%
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 2 | 7 | 10 |
| Oscillators | Bearish | 2 | 7 | 0 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Bearish
Bearish
2
Neutral
7
Bullish
0
Overall
Strong Bullish
Bearish
2
Neutral
7
Bullish
10
Moving Averages
Strong Bullish
Bearish
0
Neutral
0
Bullish
10
Key readings
- RSI (14)
- 55.47
- Neutral
- MACD (12,26,9)
- 1.91
- Bearish
- SMA (50)
- 100.93
- Bullish
- SMA (200)
- 82.78
- Bullish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +6.73% |
|---|---|
| 5Y | +6.29% |
| 3Y | +4.05% |
| 1Y | −0.42% |
| TTM | −7.69% |
Net profit
| 10Y | +14.87% |
|---|---|
| 5Y | −10.59% |
| 3Y | 0.00% |
| 1Y | 0.00% |
| TTM | +0.24% |
Operating cash flow
| 10Y | +5.24% |
|---|---|
| 5Y | +14.87% |
| 3Y | Turned positive |
| 1Y | 0.00% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +1.07 pp |
|---|---|
| 5Y | +0.04 pp |
| 3Y | −0.43 pp |
| 1Y | +0.85 pp |
| TTM | +0.88 pp |
Revenue by year
| Mar 2017 | ₹396 Cr |
|---|---|
| Mar 2018 | ₹349 Cr |
| Mar 2019 | ₹354 Cr |
| Mar 2020 | ₹298 Cr |
| Mar 2021 | ₹348 Cr |
| Mar 2022 | ₹493 Cr |
| Mar 2023 | ₹419 Cr |
| Mar 2024 | ₹396 Cr |
| Mar 2025 | ₹474 Cr |
| Mar 2026 | ₹472 Cr |
Net profit by year
| Mar 2017 | ₹5.00 Cr |
|---|---|
| Mar 2018 | ₹6.00 Cr |
| Mar 2019 | ₹7.00 Cr |
| Mar 2020 | ₹6.00 Cr |
| Mar 2021 | ₹7.00 Cr |
| Mar 2022 | ₹7.00 Cr |
| Mar 2023 | ₹4.00 Cr |
| Mar 2024 | ₹5.00 Cr |
| Mar 2025 | ₹4.00 Cr |
| Mar 2026 | ₹4.00 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 50.96 | 57.83 | 76.48 | 210 | 127 | 105 | 134 | 108 | 102 | 84.16 | 96.43 | 189 | 44.63 |
| Expenses | 49.62 | 55.99 | 73.78 | 212 | 126 | 101 | 132 | 112 | 101 | 81.52 | 97.94 | 185 | 43.31 |
| Operating Profit | 1.34 | 1.84 | 2.7 | −1.44 | 1.18 | 3.72 | 2.2 | −4.21 | 1.71 | 2.64 | −1.51 | 4.34 | 1.32 |
| OPM % | 2.63% | 3.18% | 3.53% | −0.68% | 0.93% | 3.54% | 1.64% | −3.89% | 1.67% | 3.14% | −1.57% | 2.29% | 2.96% |
| Other Income | 0.7 | 0.84 | 0.29 | 5.14 | 1.58 | 0.02 | 0.68 | 7.54 | 1.55 | 0.79 | 4.18 | −0.43 | 1.72 |
| Interest | 0.89 | 1.27 | 1.06 | 1.15 | 0.96 | 1.51 | 0.9 | 1.3 | 1.04 | 1.26 | 0.92 | 1.78 | 1.67 |
| Depreciation | 0.42 | 0.41 | 0.47 | 0.4 | 0.47 | 0.49 | 0.58 | 0.41 | 0.49 | 0.69 | 0.83 | 0.85 | 0.85 |
| PBT | 0.72 | 1 | 1.47 | 2.15 | 1.33 | 1.75 | 1.4 | 1.63 | 1.73 | 1.48 | 0.92 | 1.28 | 0.52 |
| Tax % | 0% | −22% | 30.14% | −0.47% | 6.77% | 8.62% | 48.57% | 71.6% | 20.81% | 31.08% | 38.04% | −21.88% | −98.08% |
| Net Profit | 0.72 | 1.23 | 1.02 | 2.15 | 1.24 | 1.6 | 0.72 | 0.47 | 1.37 | 1.02 | 0.57 | 1.56 | 1.02 |
| EPS (₹) | 0.28 | 0.48 | 0.4 | 0.77 | 0.44 | 0.57 | 0.25 | 0.17 | 0.48 | 0.36 | 0.2 | 0.55 | 0.36 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 213 | 246 | 396 | 349 | 354 | 298 | 348 | 493 | 419 | 396 | 474 | 472 | 415 |
| Expenses | 212 | 245 | 386 | 342 | 347 | 294 | 344 | 481 | 411 | 391 | 471 | 465 | 408 |
| Operating Profit | 1 | 1 | 10 | 8 | 8 | 3 | 5 | 11 | 8 | 4 | 3 | 7 | 7 |
| OPM % | 0.6% | 0.4% | 2.4% | 2.2% | 2.2% | 1.1% | 1.3% | 2.3% | 1.8% | 1.1% | 0.6% | 1.5% | 1.6% |
| Other Income | 3 | 3 | 3 | 3 | 4 | 7 | 7 | 3 | 3 | 7 | 10 | 6 | 6 |
| Interest | 1 | 2 | 4 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | 4.02 | 5 | 6 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3 |
| PBT | 1 | 2 | 8 | 8 | 9 | 7 | 8 | 10 | 6 | 5 | 6 | 5 | 4 |
| Tax % | 23% | 29% | 31% | 25% | 27% | 20% | 21% | 35% | 37% | 12% | 34% | 27% | — |
| Net Profit | 1 | 1 | 5 | 6 | 7 | 6 | 7 | 7 | 4 | 5 | 4 | 4 | 4 |
| EPS (₹) | 0.65 | 0.77 | 3.02 | 2.64 | 2.8 | 2.48 | 2.78 | 2.58 | 1.49 | 1.67 | 1.42 | 1.4 | 1.47 |
| Div. Payout % | 0% | 0% | 0% | 0% | 4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 17 | 17 | 18 | 23 | 23 | 23 | 23 | 25 | 25 | 28 | 28 | 28 |
| Reserves | 19 | 20 | 31 | 57 | 63 | 69 | 75 | 88 | 92 | 105 | 110 | 122 |
| Borrowings | 11 | 15 | 10 | 3 | 16 | 18 | 18 | 14 | 38 | 31 | 35 | 50 |
| Other Liabilities | 69 | 74 | 83 | 86 | 43 | 84 | 116 | 117 | 136 | 139 | 117 | 97 |
| Total Liabilities | 115 | 125 | 142 | 170 | 146 | 194 | 233 | 245 | 291 | 303 | 291 | 297 |
| Fixed Assets | 6 | 8 | 12 | 12 | 12 | 12 | 14 | 14 | 14 | 13 | 16 | 26 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 |
| Other Assets | 109 | 117 | 130 | 157 | 133 | 181 | 218 | 230 | 277 | 289 | 272 | 269 |
| Total Assets | 115 | 125 | 142 | 170 | 146 | 194 | 233 | 245 | 291 | 303 | 291 | 297 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 3 | 6 | 1 | −20 | 1 | 3 | 5 | 0 | −1 | −3 | 10 | 10 |
| Investing | −2 | −3 | −5 | −1 | −1 | −1 | −3 | −3 | 0 | −2 | −6 | −12 |
| Financing | −2 | −2 | 4 | 23 | −2 | −2 | −2 | 2 | 1 | 6 | −4 | 2 |
| Net Cash Flow | −1 | 1 | −1 | 2 | −3 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Free Cash Flow | 1 | 3 | −4 | −21 | −1 | 2 | 3 | −2 | −2 | −4 | 5 | −2 |
| CFO/EBITDA | 239 | 560 | 28 | −232 | 37 | 135 | 154 | 36 | 13 | −37 | 421 | 164 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 114 | 108 | 75 | 100 | 109 | 118 | 170 | 101 | 165 | 170 | 103 | 100 |
| Inventory Days | 7 | 3 | 5 | 16 | 23 | 21 | 20 | 11 | 26 | 33 | 36 | 33 |
| Days Payable | 117 | 108 | 71 | 84 | 40 | 98 | 120 | 86 | 115 | 123 | 81 | 66 |
| Cash Conversion Cycle | 5 | 3 | 9 | 32 | 92 | 42 | 69 | 26 | 76 | 80 | 58 | 68 |
| Working Capital Days | 49 | 40 | 34 | 69 | 77 | 99 | 91 | 68 | 89 | 106 | 89 | 90 |
| ROCE % | 7% | 7% | 22% | 14% | 12% | 8% | 9% | 10% | 6% | 6% | 6% | 6% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Aarey Drugs & Pharmaceuticals insights
66 extracted metrics across FY10–FY27.
Documents
- 27 May 2026
- 26 Aug 2025
- 4 Mar 2025
- 29 May 2024
- 23 Feb 2024
- General announcements 8 Oct 2026
Frequently Asked Questions about Aarey Drugs & Pharmaceuticals
What does Aarey Drugs & Pharmaceuticals Ltd do?
Incorporated in 1990, Aarey Drugs & Pharmaceuticals Ltd is a manufacturer of API / Bulk Drugs and offers products for diverse industrial applications
Where is Aarey Drugs & Pharmaceuticals Ltd (AAREYDRUGS) listed?
Aarey Drugs & Pharmaceuticals Ltd trades as AAREYDRUGS on the NSE and under code 524412 on the BSE.
Which sector does Aarey Drugs & Pharmaceuticals Ltd belong to?
Aarey Drugs & Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Aarey Drugs & Pharmaceuticals Ltd?
Over the last 52 weeks Aarey Drugs & Pharmaceuticals Ltd has traded between ₹50.31 and ₹114.8 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Aarey Drugs & Pharmaceuticals Ltd?
Aarey Drugs & Pharmaceuticals Ltd reported a return on equity of 2.75%. Its debt-to-equity ratio is 0.33.
Company Information
Incorporated in 1990, Aarey Drugs & Pharmaceuticals Ltd is a manufacturer of API / Bulk Drugs and offers products for diverse industrial applications
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/AAREYDRUGS.md for Aarey Drugs & Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.